Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases.
Jae-Won HyunHye Lim LeeWoo Kyo JeongHye Jung LeeJong Hwa ShinJu-Hong MinByoung Joon KimSeung Woo KimHa Young ShinJeeyoung OhWoojun KimHyun-June ShinSun-Young OhHyunjin KimYoung-Min LimSo-Young HuhEun Bin ChoTai-Seung NamSeung-Han LeeSun-Young KimSa-Yoon KangSuk Geun HanEun Hee SohnSeol-Hee BaekByung-Jo KimSang-Soo LeeJin Myoung SeokYoon-Ho HongSeong-Il OhJong Kuk KimKyong Jin ShinOhyun KwonJoong-Yang ChoJong Seok BaeSo Yeon KimYeseul KimMin Young LeeSu-Hyun KimHo Jin KimPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2020)
We aimed to compare seroprevalence of anti-myelin oligodendrocyte glycoprotein (MOG) and anti-aquaporin-4 (AQP4) antibodies in Korean adults with inflammatory demyelinating diseases (IDDs) of the central nervous system (CNS), based on a multicenter nationwide database. Sera were analyzed using a live cell-based assay for MOG and AQP4 antibodies. Of 586 Korean adults with IDDs of the CNS, 36 (6.1%) and 185 (31.6%) tested positive for MOG and AQP4 antibodies, respectively. No participant showed double positivity. Seroprevalence of MOG antibodies was about five times lower than that of AQP4 antibodies in a large cohort of Korean adults with IDDs of the CNS.